"I'm inclined to think this paves the way for a smooth transition should Teva elect not to proceed with the trial beyond the interim analysis stage"
Is this your view Madam ? Of course it is ..your so lightning quick at "analysis" ...you leave other commentators for dust.
The reason provided by our CEO is as follows:
"Targeting patients at high risk of HF-MACE and advanced heart failure could facilitate the shortest Phase 3 program, the fastest time to market, and the opportunity for the most attractive pricing".
Making a difference to the very high sick patients - is not a good reason ? (AND if that gets us to market earlier that would be a huge bonus to all Stakeholders ).
BUT your analysis/reason is of course "transitioning for Teva in case they pull out".
Something doesn't feel right here again ?
GLTAH
Timeframe for 2015, page-48
-
- There are more pages in this discussion • 23 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.23 |
Change
-0.073(5.56%) |
Mkt cap ! $1.364B | |||
| Open | High | Low | Value | Volume |
| $1.27 | $1.30 | $1.17 | $13.21M | 10.75M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 14 | 94958 | $1.23 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.24 | 43197 | 13 |
View Market Depth
| Last trade - 12.37pm 24/07/2024 (20 minute delay) ? |
| MSB (ASX) Chart |